Oral tazarotene delivers lasting results for plaque psoriasis

Washington - According to a poster study presented at the annual American Academy of Dermatology meeting, oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.) gives patients with plaque psoriasis significant improvements that continue after treatment stops. The blinded, placebo-controlled multicenter study of approximately 700 patients shows that oral tazarotene delivers several advantages over existing alternatives for treating plaque psoriasis.